Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: A novel mechanism of action?

Pharmacogenomics Journal

Volumn 5, Issue 5, 2005, Pages 298-304

  Ferno J ^a,b   Raeder, M B ^a,b   Vik Mo, A O ^a,b   Skrede, S ^a,b   Glambek, M ^a,b   Tronstad, K J ^a   Breilid, H ^a,b   Lovlie R ^a,b   Berge, R K ^a   Stansberg, C ^a,b   Steen, Vidar Martin ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Antipsychotics; Lipogenesis; Mechanism of action; Schizophrenia

Indexed keywords

ACYL COENZYME A DESATURASE; CHOLESTEROL; CLOZAPINE; FATTY ACID; FATTY ACID SYNTHASE; GERANYLTRANSFERASE; HALOPERIDOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A SYNTHASE; ISOPENTENYL DIPHOSPHATE DELTA ISOMERASE; LANOSTEROL SYNTHASE; MEVALONATE KINASE; SQUALENE MONOOXYGENASE; SQUALENE SYNTHASE; STEROL 14ALPHA DEMETHYLASE; STEROL REGULATORY ELEMENT BINDING PROTEIN; TRIACYLGLYCEROL;

ARTICLE; CANCER CELL CULTURE; CELL LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DNA MICROARRAY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; ENZYME ACTIVITY; FATTY ACID SYNTHESIS; GENE CONTROL; GENE EXPRESSION REGULATION; GLIOMA CELL; HUMAN; HUMAN CELL; LIPOGENESIS; METABOLIC DISORDER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; UPREGULATION;

ANTIPSYCHOTIC AGENTS; CELL LINE, TUMOR; CHOLESTEROL; CLOZAPINE; FATTY ACID SYNTHETASE COMPLEX; FATTY ACIDS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HALOPERIDOL; HUMANS; HYDROXYMETHYLGLUTARYL-COA SYNTHASE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA; SCHIZOPHRENIA; TIME FACTORS; UP-REGULATION;

EID: 27144450193     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500323     Document Type: Article

References (43)

1. Freedman R. Schizophrenia. N Engl J Med 2003; 349: 1738-1749.
2. Mueser KT, McGurk SR. Schizophrenia. Lancet 2004; 363: 2063-2072.
3. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol Psychiatry 2005; 10: 40-68.
4. Nelson MD, Saykin AJ, Flashman LA, Riordan HJ. Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: A meta-analytic study. Arch Gen Psychiatry 1998; 55: 433-440.
5. Wright IC, Rabe-Hesketh S, Woodruff PW, David AS, Murray RM, Bullmore ET. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 2000; 157: 16-25.
6. Zipursky RB, Lambe EK, Kapur S, Mikulis DJ. Cerebral gray matter volume deficits in first episode psychosis. Arch Gen Psychiatry 1998; 55: 540-546.
7. Szeszko PR, Goldberg E, Gunduz-Bruce H, Ashtari M, Robinson D, Malhotra AK et al. Smaller anterior hippocampal formation volume in antipsychotic-naive patients with first-episode schizophrenia. Am J Psychiatry 2003; 160: 2190-2197.
8. Kasai K, Shenton ME, Salisbury DF, Hirayasu Y, Onitsuka T, Spencer MH et al. Progressive decrease of left Heschl gyrus and planum temporale gray matter volume in first-episode schizophrenia: A longitudinal magnetic resonance imaging study. Arch Gen Psychiatry 2003; 60 766-775.
9. Harrison P, Lewis DA. Neuropathology of schizophrenia. In: Hirsch S, Weinberger DR (eds). Schizophrenia, 2nd edn. Blackwell Science: Oxford, UK, 2003 pp. 310-325.
10. Liddle P, Pantelis C. Brain imaging in schizophrenia. In: Hirsch S, Weinberger DR (eds). Schizophrenia, 2nd edn. Blackwell Science: Oxford, UK, 2003 pp. 403-417.
11. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA 2001; 98: 4746-4751.
12. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003; 362: 798-805.
13. Aston C, Jiang L, Sokolov BP. Microarray analysis of postmortem temporal cortex from patients with schizophrenia. J Neurosci Res 2004; 77: 858-866.
14. Schmitt A, Wilczek K, Blennow K, Maras A, Jatzko A, Petroianu G et al. Altered thalamic membrane phospholipids in schizophrenia: A post-mortem study. Biol Psychiatry 2004; 56: 41-45.
15. Dietschy JM, Turley SD. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 2004; 45: 1375-1397.
16. Ness GC. Developmental regulation of the expression of genes encoding proteins involved in cholesterol homeostasis. Am J Med Genet 1994; 50: 355-357.
17. Verheijen MH, Chrast R, Burrola P, Lemke G. Local regulation of fat metabolism in peripheral nerves. Genes Dev 2003; 17: 2450-2464.
18. Mauch DH, Nagler K, Schumacher S, Goritz C, Muller EC, Otto A et al. CNS synaptogenesis promoted by glia-derived cholesterol. Science 2001; 294: 1354-1357.
19. Koudinov AR, Koudinova NV. Essential role for cholesterol in synaptic plasticity and neuronal degeneration. FASEB J 2001; 15: 1858-1860.
20. Hayashi H, Campenot RB, Vance DE, Vance JE. Glial lipoproteins stimulate axon growth of central nervous system neurons in compartmented cultures. J Biol Chem 2004; 279: 14009-14015.
21. Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof PR et al. White matter changes in schizophrenia: Evidence for myelin-related dysfunction. Arch Gen Psychiatry 2003; 60: 443-456.
22. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005; 10: 79-104.
23. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials. Am J Psychiatry 2001; 158: 518-526.
24. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC et al. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-1696.
25. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 2003; 28(Suppl 1): 83-96.
26. Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004; 65(Suppl 7): 4-18, (quiz 19-20).
27. Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: Literature review and clinical implications. Drugs 2004; 64: 701-723.
28. Akslen LA, Andersen KJ, Bjerkvig R. Characteristics of human and rat glioma cells grown in a defined medium. Anticancer Res 1988; 8 797-803.
29. Brown MS, Goldstein JL, Dietschy JM. Active and inactive forms of 3-hydroxy-3-methylglutaryl coenzyme A reductase in the liver of the rat. Comparison with the rate of cholesterol synthesis in different physiological states. J Biol Chem 1979; 254: 5144-5149.
30. Shimano H. Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes. Prog Lipid Res 2001; 40: 439-452.
31. Horton JD, Goldstein JL, Brown MS. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-1131.
32. Rawson RB. The SREBP pathway - insights from Insigs and insects. Nat Rev Mol Cell Biol 2003; 4: 631-640.
33. Shimomura I, Shimano H, Horton JD, Goldstein JL, Brown MS. Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J Clin Invest 1997; 99: 838-845.
34. Salles J, Sargueil F, Knoll-Gellida A, Witters LA, Cassagne C, Garbay B. Acetyl-CoA carboxylase and SREBP expression during peripheral nervous system myelination. Biochim Biophys Acta 2003; 1631: 229-238.
35. Lange Y, Steck TL. Cholesterol homeostasis. Modulation by amphiphiles. J Biol Chem 1994; 269: 29371-29374.
36. Lange Y, Ye J, Rigney M, Steck TL. Regulation of endoplasmic reticulum cholesterol by plasma membrane cholesterol. J Lipid Res 1999; 40: 2264-2270.
37. Adams CM, Goldstein JL, Brown MS. Cholesterol-induced conformational change in SCAP enhanced by Insig proteins and mimicked by cationic amphiphiles. Proc Natl Acad Sci USA 2003; 100: 10647-10652.
38. Radhakrishnan A, Sun LP, Kwon HJ, Brown MS, Goldstein JL. Direct binding of cholesterol to the purified membrane region of SCAP: Mechanism for a sterol-sensing domain. Mol Cell 2004; 15: 259-268.
39. Thomas EA, George RC, Danielson PE, Nelson PA, Warren AJ, Lo D et al. Antipsychotic drug treatment alters expression of mRNAs encoding lipid metabolism-related proteins. Mol Psychiatry 2003; 8: 983-993, 950.
40. Sanfilipo M, Lafargue T, Rusinek H, Arena L, Loneragan C, Lautin A et al. Volumetric measure of the frontal and temporal lobe regions in schizophrenia: Relationship to negative symptoms. Arch Gen Psychiatry 2000; 57: 471-480.
41. Sigmundsson T, Suckling J, Maier M, Williams S, Bullmore E, Greenwood K et al. Structural abnormalities in frontal, temporal, and limbic regions and interconnecting white matter tracts in schizophrenic patients with prominent negative symptoms. Am J Psychiatry 2001; 158: 234-243.
42. Finelli PF. Metachromatic leukodystrophy manifesting as a schizophrenic disorder: Computed tomographic correlation. Ann Neurol 1985; 18 94-95.
43. Hyde TM, Ziegler JC, Weinberger DR. Psychiatric disturbances in metachromatic leukodystrophy. Insights into the neurobiology of psychosis. Arch Neurol 1992; 49: 401-406.